Protalix BioTherapeutics Eligible for $20 Million Milestone Payment
By Chris Wack
Protalix BioTherapeutics said Thursday that it is eligible to receive a $20 million milestone payment from its commercial partner, Chiesi Global Rare Diseases, a business unit of the Chiesi Group.
The company said the milestone payment was triggered by the approval by the U.S. Food and Drug Administration of Elfabrio pegunigalsidase alfa-iwxj for the treatment of adult patients with Fabry disease.
The FDA's approval was announced May 10, 2023, and the milestone payment is payable within 30 days of the FDA approval date.
In July 2018, the company entered into an exclusive license and supply agreement with Chiesi Farmaceutici, where it granted Chiesi an exclusive license to commercialize pegunigalsidase alfa in the U.S.
Protalix has already received a total of $95 million in upfront payments and to cover development costs.
On a proforma basis, including the receipt of the $20 million milestone payment, Protalix has cash and cash equivalents of $51.6 million as of Thursday.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
May 18, 2023 07:13 ET (11:13 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
After Earnings, Is Coke Stock a Buy, a Sell, or Fairly Valued?
-
Disney Earnings: Improved Streaming Results Come at the Expense of Continued Linear Weakness
-
Apple: We Expect New Models and New Chip to Spur Return to iPad Growth
-
Palantir Earnings: AI Platform Drives Strong Start to 2024
-
What I Hope My 14-Year-Old Learned at Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Amazon Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Dividend Stocks
-
3 Stocks With High Dividend Yields That Warren Buffett Likes